ImmunoACT has joined hands with Mango Sciences to launch what they describe as the world’s first “bridge financing” and “value-based offering” for CAR-T therapy in India. This partnership is aimed at broadening patient access to advanced, cutting-edge cancer treatment, specifically their lead product NexCAR19, by significantly reducing financial barriers for patients in need.
Under this new model, eligible patients can avail of a 0%-interest EMI plan covering up to ₹10 lakh to help meet the cost of treatment. On top of that, there is a value-based component also extending up to ₹10 lakh for clinically eligible patients, helping ensure that financial constraints do not stand in the way of access to potentially life-saving therapy.
The background to this partnership lies in NexCAR19’s status: it is India’s first home-developed CAR-T cell therapy, originally granted regulatory approval by the Central Drugs Standard Control Organization (CDSCO) in October 2023 for use in relapsed or refractory B-cell leukemias and lymphomas.
Previously, the therapy was typically priced in the ballpark of ₹30–40 lakh per dose.
Through the new financing initiative, ImmunoACT and Mango Sciences hope to lower upfront cost barriers and make the therapy more accessible, especially for patients who would otherwise struggle to afford the therapy under one-time payment models. The offering will initially be available in select healthcare facilities across India.
This development represents a potentially pivotal shift in how high-end gene and cell therapies are made available in India — marrying advanced biotech innovation with financial tools to improve accessibility. Over time, if widely adopted, this model could significantly broaden access to CAR-T therapy for patients battling blood cancers in the country.
